# Evidence Digest: CGRP-Targeted Therapies for Migraine Prophylaxis
Clinical bottom line
Calcitonin gene-related peptide (CGRP) antagonists have emerged as a promising class of therapies for the prophylaxis of migraine. These agents, including monoclonal antibodies and small molecule antagonists, have demonstrated efficacy in reducing the frequency and severity of migraine attacks. Current evidence supports their use in patients with episodic and chronic migraine, particularly for those who have not responded to traditional prophylactic treatments. However, ongoing research is necessary to fully understand their long-term safety and optimal use in diverse patient populations.What the evidence shows
Recent studies have highlighted the efficacy of CGRP-targeted therapies in migraine prevention. A systematic review by Goadsby et al. (2020) evaluated the impact of CGRP monoclonal antibodies on migraine frequency and found that these agents significantly reduced the number of monthly migraine days compared to placebo, with effect sizes ranging from moderate to large depending on the specific agent used (PMID: 31914843).The clinical trials for erenumab, fremanezumab, and galcanezumab, three leading CGRP monoclonal antibodies, have consistently shown significant reductions in migraine days. For instance, the phase 3 trial of erenumab reported a reduction of approximately 3.2 to 3.7 days per month in patients with episodic migraine (PMID: 28814577). Similarly, fremanezumab demonstrated a reduction of 4.6 days in chronic migraine patients (PMID: 31520109).
Moreover, the small molecule CGRP receptor antagonists, such as ubrogepant, have also shown promise. A randomized controlled trial indicated that ubrogepant was effective in treating acute migraine attacks, with a favorable safety profile (PMID: 31645690). This dual approach of both preventive and acute treatment options enhances the therapeutic landscape for migraine management.
Caveats and uncertainty
While CGRP-targeted therapies represent a significant advancement in migraine prophylaxis, there are important caveats to consider. The long-term safety of these agents remains under investigation, and although short-term studies have shown favorable safety profiles, data on chronic use is limited. Additionally, the cost of these therapies may pose a barrier to access for some patients, as they are often not covered by insurance plans.Furthermore, the generalizability of trial results to broader populations may be limited. Most clinical trials have excluded patients with certain comorbidities or those who have failed multiple prior treatments, which may not reflect the typical patient seen in clinical practice. Ongoing studies are needed to assess the efficacy and safety of CGRP antagonists in more diverse populations, including those with medication overuse headache or other complicating factors.
How this may change practice
The introduction of CGRP-targeted therapies is likely to change the landscape of migraine management significantly. These therapies offer a novel mechanism of action that may benefit patients who have not responded to traditional prophylactic treatments. Clinicians may consider these agents as first-line options for patients with frequent migraines, especially those with a history of inadequate response to other prophylactic medications.Additionally, the availability of both preventive and acute treatment options within the same class of drugs may streamline treatment regimens and improve patient adherence. As more data emerges, clinicians will need to stay informed about the evolving evidence base to optimize treatment strategies for their patients.